Salix strikes $12M licensing deal for bowel prep drug
Related Blog Posts
- Salix prevails in $150M suit filed by drug partner
- NBC picks Durham firm for Olympics; Bioventus acquisition; Salix patent; Decker to N.C. Wireless Center; Cornerstone acquired; wireless carrier rankings out
- FDA accepts new drug filing for Salix rectal inflammation drug
- Expanding Salix sales force expected to grow drug sales to $1.6B in 2014
- Salix closes on $2.6B deal for San Diego pharma Santarus
- Exclusive analysis: Gastrointestinal pharma Salix still hungry for more deals
- Salix to acquire San Diego pharma Santarus for $2.6B
Raleigh, N.C. — Raleigh-based Salix Pharmaceuticals, which focuses on gastrointestinal treatments, is adding another product to its lineup.
The deal, which was announced early Thursday, calls for Salix to pay an upfront fee of $7 million and $5 million in milestone payments plus royalties.
In return, Salix gains worldwide rights to RHB-106, an encapsulated bowl prep.
Salix recently filed a New Drug Application with the FDA for a rectal inflammation drug and closed on a $2.6 billion acquisition of
“Salix is pleased to enter this strategic collaboration with RedHill and to secure what we believe could be the first prescription encapsulated bowel prep product,” said Carolyn Logan, chief executive officer at Salix. “Many patients find the taste and palatability of current bowel prep products to be unacceptable. We believe the availability of a tasteless solid oral formulation bowel prep, if approved by the FDA, could potentially go a long way in helping to increase patient compliance and to ease patient burden associated with bowel cleansing prior to various medically important abdominal procedures.”
The deal entrusts commercialization of the drug, which is in late clinical trial testing, to Salix.
Dror Ben-Asher, RedHill Biopharma's CEO, noted in the announcement: "The licensing transaction with Salix is an important milestone for RedHill and yet another validation of our business model. This is the first licensing deal derived from RedHill's late clinical-stage pipeline, and we are confident that Salix, a leading company in the gastrointestinal field with a proven track record in drug development and commercialization, is the right partner. I would like to thank our shareholders for their continued support and RedHill’s team for their hard work and dedication towards the realization of this important transaction."
RedHill describes RHB-106 as "an encapsulated formulation intended for the preparation and cleansing of the gastrointestinal tract prior to the performance of abdominal procedures, including diagnostic tests, such as colonoscopy, barium enema or virtual colonoscopy, as well as surgical interventions, such as laparotomy. The RHB-106 preparation is a tasteless solid oral dosage potentially allowing an unobstructed procedure with reduced side-effects and improved compliance. It avoids patient exposure to the often unacceptable taste of current products."
Please Log In to add a comment.
Best of TechWire Insider
- IBM's top chef tries new board recipe with 'presiding director;' company won't comment
- Startup Factory's search for 'bad-a**' entrepreneurs finds 4 teams
- A mentor becomes a partner: How Silverpop CEO boosts Windsor Circle
- No Ashton Kutcher smartphone, Lenovo says
- Checking in on 'tattooed guy' with SXSW-bound Raleigh team
- Sneak peek: Stylish HQRaleigh on eve of move-in day
- Raleigh mayor heads to Austin to recruit entrepreneurs, businesses
- Reports: Strike against IBM-Lenovo deal continues in China
- RTP misses out on $100M Cisco 'Internet of Everything' center
- IBM job protests in China don't generate sympathy in US